SUPN - Supernus approaches LOE for Trokendi but Jefferies sees 'a new product cycle'

After a ~1.2% loss yesterday despite the FDA approval for Qelbree in attention-deficit hyperactivity disorder (“ADHD”) in those aged 6 – 17 years, Supernus Pharmaceuticals ([[SUPN]] +9.0%) is trading sharply higher today.Based on two surveys conducted by the firm, Jefferies has upgraded the stock to buy from hold expecting a larger-than-expected potential for the treatment which is on track for a commercial rollout in H2 2022.Ahead of loss of exclusivity for Trokendi XR’s in 2023, Supernus with the FDA approval now stands ‘on the cusp of a new product cycle,’ wrote the analyst Derik de Bruin with its price target raised by ~60.0% to $9.00 per share implying ~43.0% premium to the previous close.Based on a physician survey and payer survey, the analyst predicts the treatment to achieve better than expected uptake by physicians driven by ‘unrestricted access for appropriate rebates.’In H2 2021, Supernus plans to submit a marketing application for

For further details see:

Supernus approaches LOE for Trokendi, but Jefferies sees ‘a new product cycle’